Gerling Marco, Meyer Karl F, Fuchs Katrin, Igl Bernd W, Fritzsche Britta, Ziegler Andreas, Bader F, Kujath Peter, Schimmelpenning Hendrik, Bruch Hans-Peter, Roblick Uwe J, Habermann Jens K
Laboratory for Surgical Research, Department of Surgery, University Clinic Schleswig-Holstein, Lübeck, Germany.
Ann Surg. 2010 Jul;252(1):74-83. doi: 10.1097/SLA.0b013e3181deb664.
Aneuploidy is an independent risk factor for forthcoming carcinogenesis in ulcerative colitis (UC). An inferior prognosis of patients with ulcerative colitis-associated colorectal cancer (UCC) compared with those with sporadic colorectal cancer (SCC) has been reported, but remains controversial. This prompted us to investigate if aneuploidy can be observed in UCCs as frequently as in their sporadic counterpart and if aneuploidy per se might be a driving feature of poor prognosis in UCC.
We obtained clinical follow-up for 257 SCC patients (average observation time 57 months) and 31 UCC patients (51 months). Touch preparation slides or tissue sections were prepared of all 288 carcinomas for ploidy analysis.
Ploidy status was assessed for 260 SCCs and 31 UCCs by image cytometry and correlated to clinical features. Survival data were analyzed using Kaplan-Meier estimates.
Aneuploidy was detected in 74.6% of SCCs and in all 31 UCCs. Logistic regression analysis yielded age (odds ratio [OR], 1.05; 95% CI, 1.02-1.09; P = 0.003) and aneuploidy (OR, 4.07; 95% CI, 1.46-11.36; P = 0.007) as independent prognostic factors for R0-resected patients devoid of metastases. Diploid SCCs had a more favorable 5-year survival (88.2%) than aneuploid SCCs (69.0%) and UCCs (73.1%) (P = 0.074).
UC-associated carcinomas presented aneuploidy at significantly higher frequency than sporadic colorectal carcinomas (P < 0.0006). UCCs and aneuploid SCCs share a similar prognosis inferior to that of diploid SCCs. Aneuploidy proved to be the strongest independent prognostic marker for R0-resected colorectal cancer patients overall.
非整倍体是溃疡性结肠炎(UC)未来发生癌变的独立危险因素。据报道,溃疡性结肠炎相关结直肠癌(UCC)患者的预后比散发性结直肠癌(SCC)患者差,但仍存在争议。这促使我们研究UCC中是否能像散发性结直肠癌那样频繁观察到非整倍体,以及非整倍体本身是否可能是UCC预后不良的驱动因素。
我们对257例SCC患者(平均观察时间57个月)和31例UCC患者(51个月)进行了临床随访。对所有288例癌组织制作了触摸涂片玻片或组织切片进行倍体分析。
通过图像细胞术评估260例SCC和31例UCC的倍体状态,并与临床特征相关联。使用Kaplan-Meier估计法分析生存数据。
在74.6%的SCC和所有31例UCC中检测到非整倍体。逻辑回归分析得出年龄(优势比[OR],1.05;95%可信区间,1.02 - 1.09;P = 0.003)和非整倍体(OR,4.07;95%可信区间,1.46 - 11.36;P = 0.007)是无转移的R0切除患者的独立预后因素。二倍体SCC的5年生存率(88.2%)比非整倍体SCC(69.0%)和UCC(73.1%)更有利(P = 0.074)。
UC相关癌中非整倍体出现的频率明显高于散发性结直肠癌(P < 0.0006)。UCC和非整倍体SCC的预后相似,均不如二倍体SCC。对于R0切除的结直肠癌患者,非整倍体被证明是最强的独立预后标志物。